Last reviewed · How we verify
BLU-5937 IR — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BLU-5937 IR (BLU-5937 IR) — Bellus Health Inc. - a GSK company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BLU-5937 IR TARGET | BLU-5937 IR | Bellus Health Inc. - a GSK company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BLU-5937 IR CI watch — RSS
- BLU-5937 IR CI watch — Atom
- BLU-5937 IR CI watch — JSON
- BLU-5937 IR alone — RSS
Cite this brief
Drug Landscape (2026). BLU-5937 IR — Competitive Intelligence Brief. https://druglandscape.com/ci/blu-5937-ir. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing